Publications
Montoya T, Lee JV, Qiu L, Krall A, Matulionis N, Seo Y, Finck BN, Kelley RK, Christofk H, Goga A. Alanine catabolism as a targetable vulnerability for MYC-driven liver cancer. bioRxiv : the preprint server for biology. 2025. PMID: 40766546
Sullivan RJ, Tsai KK, Pavlick AC, Buchbinder EI, Agarwala SS, Ribas A, Jansson J, Rossiter G, Olszanski AJ. Phase 1b Study of Tovorafenib, Plozalizumab or Vedolizumab Plus Standard-of-Care Immune Checkpoint Inhibitors in Patients with Advanced Melanoma. Journal of Cancer. 2025. PMID: 41049010
Navari RM, Tyler T, Inui N, Iihara H, Bonizzoni E, Park YH, Rugo HS, Roeland EJ. Individual patient data meta-analysis of NEPA versus aprepitant-based antiemetic regimens for preventing chemotherapy-induced nausea and vomiting. Future oncology (London, England). 2025. PMID: 40782019
Nira Krasnow, Michelle Jayaraj, Mia Salans, Kelsey Kuwahara, Maggie Zhou, Samantha Fisch, Lauren Boreta, Steve Braunstein, Ramin Morshed, Harish Vasudevan, Jo Chien, Melanie Majure, Hope Rugo, Michelle Melisko, Laura Huppert. TRLS-13 CLINICAL CHARACTERISTICS AND OVERALL SURVIVAL OF PATIENTS WITH METASTATIC BREAST CANCER AND BRAIN METASTASES: A SINGLE CENTER RETROSPECTIVE COHORT STUDY. Neuro-oncology advances. 2025. PMID:
Li M, Kelley RK. Immunotherapy and cirrhosis - expanding Child-Pugh boundaries in liver cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2025. PMID: 40779207
Venkatesh H, Fong L. CD4+ T cell dysfunction in cancer. The Journal of experimental medicine. 2025. PMID: 40772965
Halabi S, Guo S, Luo B, Yu C, Knutson TP, Kobilka A, Lyman J, Beltran H, Antonarakis ES, Galsky MD, Rosenberg JE, Ryan CJ, Small EJ, Kelly WK, Morris MJ, Page D, Dehm SM, Armstrong AJ. Pathogenic Genomic Alterations in Circulating Tumor DNA Predict Overall Survival in Men with Metastatic Castrate-resistant Prostate Cancer. European urology. 2025. PMID: 40774853
Zhang L, Chinnam M, Balk B, Zhang X, Wang Y, Shaurova T, Alam S, Pokharel S, Singh P, Jacobi J, Wang J, Cortes Gomez E, Habitzruther M, Seshadri M, Atanassov B, Wu W, Benevolenskaya EV, Blakely CM, Hershberger P, Long M, Bivona T, Goodrich DW. Reversible therapeutic resistance in EGFR mutant lung cancer caused by RB1 loss induced lineage plasticity. bioRxiv : the preprint server for biology. 2025. PMID: 40799547
Zhang L, Chinnam M, Balk B, Zhang X, Wang Y, Shaurova T, Alam S, Pokharel S, Singh P, Jacobi J, Wang J, Cortes Gomez E, Habitzruther M, Seshadri M, Atanassov B, Wu W, Benevolenskaya EV, Blakely CM, Hershberger P, Long M, Bivona T, Goodrich DW. Reversible therapeutic resistance in EGFR mutant lung cancer caused by RB1 loss induced lineage plasticity. bioRxiv : the preprint server for biology. 2025. PMID: 40799547
Leeman JE, Shin KY, Droznin A, Catalano P, Cagney DN, Singer L, Oniyangi RD, Zhai K, Benham G, Chirmade S, Campbell J, Boyle S, Saranteas A, Williams CL, Huynh E, Han Z, Sudhyadhom A, Hu YH, Ferguson D, Singhrao K, Hsu SH, Bredfeldt J, Martin NE, Mancias JD, Mamon HJ, Van Dams R, Venkatachalam V, Tanguturi SK, Huynh MA, Fitzgerald KJ, Elhalawani H, Bitterman DS, Schoenfeld JD, Nguyen P, Haas-Kogan DA, Mak R. Stereotactic MRI Guided Adaptive Radiotherapy: a pooled analysis of a master prospective trial. Journal of the National Cancer Institute. 2025. PMID: 40794880
Rugo HS, Tokunaga E, Iwata H, Petry V, Smit EF, Goto Y, Kim DW, Shitara K, Gruden JF, Modi S, Cortés J, Krop I, Jänne PA, Cheng Y, Taitt C, Cheng FC, Powell CA. Pooled analysis of trastuzumab deruxtecan retreatment after recovery from grade 1 interstitial lung disease/pneumonitis. Annals of oncology : official journal of the European Society for Medical Oncology. 2025. PMID: 40769277
Rugo H, Bardia A, Bruno DS, Ernani V, Hamilton E, Heist R, Jhaveri K, Levy B, Lisberg A, O'Shaughnessy J, Sands J, Spira A, Tolaney S, Treister NS, Matthews C, Johnson M. US expert Delphi consensus on the prevention and management of stomatitis in patients treated with datopotamab deruxtecan. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2025. PMID: 40762824
Williams BM, Mulima G, Kaimila B, Marapese KD, Salima AW, Evans A, Ngwira N, Kajombo C, Gallaher J, Charles A, McGinty K, Buckle G, Mody GN. Esophageal Cancer Staging in Malawi: The Feasibility of Chest Radiography and Abdominal Ultrasound for Initial Evaluation. Research square. 2025. PMID: 40799736
Tolani MA, Agbo CA, Umar SS, Paciorek A, Ojewola RW, Mohammed F, Maiga M, Kaninjing E, Ahmed M, DeBoer R. An intervention mapping approach to the development and evaluation of a community-based prostate cancer early detection programme in Nigeria. PLOS global public health. 2025. PMID: 40763189
Battaglin F, O'Neil BH, Stintzing S, Ou FS, Zemla TJ, Niedzwiecki D, Innocenti F, Hochster HS, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Heintges T, Lerchenmüller C, Weiss L, Heinrich K, Goldberg RM, Mayer RJ, Schilsky RL, Blanke CD, Venook AP, Lenz HJ, Heinemann V. Outcomes for FOLFIRI plus bevacizumab or cetuximab in patients treated with oxaliplatin-based adjuvant therapy: A combined analysis of FIRE-3 and CALGB/SWOG 80405 (Alliance). European journal of cancer (Oxford, England : 1990). 2025. PMID: 40803104
Kosibaty Z, Luck C, Okimoto RA. The CIC::DUX4 oncoprotein maintains DNA integrity through direct regulation of the catalytic subunit of DNA polymerase epsilon (POLE). Oncogene. 2025. PMID: 40760094
Roy S, Ozay ZI, Guha A, Sun Y, Chi KN, Morgan SC, Malone S, Wallis CJD, Brown JR, Barata PC, Kishan AU, Jia AY, Zaorsky NG, Swami U, Chowdhury S, Small EJ, Spratt DE, Saad F, Agarwal N. Statin Use in Patients With Advanced Prostate Cancer in the TITAN and SPARTAN Trials. JAMA network open. 2025. PMID: 40833694
Iagaru A, Suarez JF, Behr S, Aggarwal R, Paredes P, Buffi N, Penhoat T, Ceci F, Walz J, Doumerc N, Coulanges M, Xu Z, Seigne C, Wilke C, Catafau AM, Fanti S, Maurer T, GuideView study investigators. Imaging Efficacy of [18F]CTT1057 PET for the Detection of PSMA-Positive Tumors Using Histopathology as Standard of Truth: Results from the GuideView Phase 2/3 Prospective Multicenter Study. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2025. PMID: 40473463
Dhakal B, Akhtar OS, Fandrei D, Jensen A, Banerjee R, Pan D, Richard S, Friend R, Rees MJ, Costello P, Vazquez Martinez MA, Pasvolsky O, Wagner CB, Davis JA, Castaneda Puglianini OA, Reshef R, Afrough A, Dima D, Bhutani M, Nadeem O, Parrondo RD, Freeman CL, Mikkilineni L, Raza S, Anderson LD, Kapoor P, Hosoya H, Chhabra S, Grajales-Cruz A, Gaballa MR, Midha S, Alsina M, Sborov DW, Patel KK, Lin Y, Ferreri CJ, Gagelmann N, Kumar AD, Hansen DK, Cowan AJ, Costa LJ, Merz M, Sidana S. Sequential Targeting in Multiple Myeloma: Talquetamab, a GPRC5D bispecific antibody, as a Bridge to BCMA CAR-T cell therapy. Blood. 2025. PMID: 40749169
Fanti S, Robles Barba JJ, Behr S, Maurer T, Paredes P, Walz J, Duch J, Perdigo MS, Mainta IC, Bonnefoy PB, Coulanges M, Tang J, Seigne C, Wilke C, Catafau AM, Iagaru A, Aggarwal R. Imaging Efficacy of [18F]CTT1057 PET/CT in Patients with Biochemically Recurrent Prostate Cancer: Results from GuidePath-A Phase 3, Prospective Multicenter Study. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2025. PMID: 40473464